首页> 外文期刊>Intelligence: A Multidisciplinary Journal >Prognostic contribution of predicted sensitivity to endocrine therapy (SET) prior to neoadjuvant chemotherapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer

【24h】

Prognostic contribution of predicted sensitivity to endocrine therapy (SET) prior to neoadjuvant chemotherapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer

机译：预测敏感性对内分泌治疗（套装）在Neoadjuvant化疗之前II-III激素受体阳性和HER2阴性（HR + / HER2-）乳腺癌的乳腺癌

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal》 |2020年第2020期|共2页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学;
关键词

相似文献

外文文献
中文文献
专利

1. Prognostic contribution of predicted sensitivity to endocrine therapy (SET) prior to neoadjuvant chemotherapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：预测敏感性对内分泌治疗（套装）在Neoadjuvant化疗之前II-III激素受体阳性和HER2阴性（HR + / HER2-）乳腺癌的乳腺癌
2. Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2-) early breast cancer (EBC): results from the GEICAM/2006-10 study [J] . Ruiz-Borrego Manuel, Guerrero-Zotano Angel, Bermejo Begona, Breast cancer research and treatment. . 2019,第1期

机译：III期通过激素受体阳性HER2阴性（HR + / HER2-）早期乳腺癌（EBC）的绝经后妇女的辅助治疗（A）评估富含富腊肠（F）作为辅助治疗的辅助治疗：来自GEICAM / 2006-10的结果学习
3. Safety and efficacy of abemaciclib plus endocrine therapy (ET) in elderly patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+, HER2-) advanced breast cancer: An age-specific subgroup analysis of MONARCH 2 and 3 trials [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：Abemaciclib Plus内分泌治疗的安全性和疗效（et）在患者激素受体阳性/人体表皮生长因子受体2阴性（HR +，Her2-）晚期乳腺癌：君主2和3次试验的年龄特异性亚组分析
4. Estrogen Receptor-Positive Breast Cancer: Traditional Prognostics, Molecular Pathology: A New Breast Cancer Taxonomy and 21st Century Personalized Prognostic and Predictive Assays [C] . Frederick L. Baehner International Symposium on Cancer Metastasis and the Lymphovascular system: Basis for Rational Therapy . 2009

机译：雌激素受体阳性乳腺癌：传统预测，分子病理：新的乳腺癌分类和21世纪个性化预测和预测测定
5. Using Preoperative Mri-guided Biopsies to Predict Pathologic Complete Response after Neoadjuvant Chemotherapy in Breast Cancer [D] . Kim, Jiyoon. 2019

机译：在乳腺癌新辅助化疗后使用术前Mri引导的活检来预测病理完全缓解
6. The Evaluation of Magee Equation 2 in Predicting Response and Outcome in Hormone Receptor-Positive and HER2-Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy [O] . Napat Saigosoom, Doonyapat Sa-nguanraksa, Eng O-charoenrat, 2020

机译：Magee方程2在预测激素受体阳性和HER2阴性乳腺癌患者接受新辅助化疗的反应和结果中的评估
7. >The Evaluation of Magee Equation 2 in Predicting Response and Outcome in Hormone Receptor-Positive and HER2-Negative Breast Cancer Patients Receiving Neoadjuvant Chemotherapy [O] . Napat Saigosoom, Doonyapat Sa-nguanraksa, Eng O-charoenrat, 2020

机译：> MAGES等式2在激素受体阳性和HER2阴性乳腺癌患者接受Neoadjuvant化疗的响应和结果中的评价

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号